Skip to content
MatchScript
Menu

Head-to-head · The Match Score

ShedRx vs eMI Aesthetics

Both scored on the same six-factor Match Score. ShedRx wins this matchup with a 86 to 68 edge.

Higher Match Score

ShedRx

#4 · Grade B+

People who want an oral or sublingual option rather than weekly injections.

Visit ShedRx
VS

eMI Aesthetics

#146 · Grade C

Shoppers wanting compounded sema or tirz in all 50 states with an ai progress simulator.

Visit eMI Aesthetics

Factor by factor

The six sub-scores behind each Match Score. The quiz reweights these to your priorities — one provider can pull ahead for you on the factors you care about.

Budget Fit
84
72
Speed to Start
84
93
Formulary Match
92
77
Support Level
86
65
Flexibility
88
55
Transparency
82
46

Price, coverage & formulary

DetailShedRxeMI Aesthetics
Semaglutide$199/mo$179/mo (all doses, compounded)
Tirzepatide$299/moNot disclosed
CoverageAll 50 statesAll 50 states
Brand-name accessCompounded onlyYes
Oral / sublingualYesYes
Match Score86 · B+68 · C
Winner: ShedRx

ShedRx edges out eMI Aesthetics, 86 to 68 on the default Match Score. A weight-focused program that also offers an oral/sublingual route for the needle-averse.

eMI Aesthetics is still a fair pick if its strengths line up with yours — best for: Shoppers wanting compounded sema or tirz in all 50 states with an ai progress simulator.

Worth a look either way: our overall #1 pick is CoreAge Rx (Match Score 91) — nationwide access, both molecules at one flat price, easy to cancel. Or take the 6-question quiz to see your personalized match.

Assume any provider we list may compensate us, at no cost to you. It never changes the Match Score.

Full ShedRx reviewFull eMI Aesthetics review

More head-to-heads

Or browse alternatives to ShedRx and all comparisons.

Pricing, states and verification reflect each provider's public disclosures at last review; the Match Score and its sub-scores are our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.